Product Description
Ketamine is used by medical practitioners and veterinarians as an anaesthetic. It's sometimes used illegally by people to get high.
Mechanisms of Action: NMDA Antagonist,Excitatory Amino Acid Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Spain, United States
Active Clinical Trial Count: 18
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bipolar Disorder|Colorectal Cancer|Depressive Disorder, Major|Digestive System Cancer|Gastrointestinal Cancer|Headache Disorders|Intestinal Diseases|Liver Cancer|Mouth Cancer|Mucositis|Oropharyngeal Cancer|Skin Cancer|Suicidality
Phase 2: Acute Pain|Depressive Disorder, Treatment-Resistant|Healthy Volunteers|Methamphetamine Dependence|Stress Disorders, Post-Traumatic
Phase 1: Depressive Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| S-21-02 (SLS-002) | P2 |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
2026-03-01 |
12% |
2025-02-14 |
Primary Endpoints |
| KARE | P2 |
Recruiting |
Methamphetamine Dependence |
2026-03-01 |
2025-03-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| KetHead | P3 |
Recruiting |
Headache Disorders |
2025-10-01 |
22% |
2024-09-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| PDC 01-0202 | P2 |
Recruiting |
Acute Pain |
2024-12-31 |
18% |
2025-05-02 |
Treatments |
| SevereBD | P3 |
Active, not recruiting |
Suicidality|Bipolar Disorder |
2024-12-31 |
31% |
2024-01-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| CTR20242441 | P1 |
Completed |
Depressive Disorder, Treatment-Resistant |
2024-10-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20232056 | P1 |
Completed |
Depressive Disorder|Suicidality |
2023-10-17 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| SLS-002-201 | P2 |
Completed |
Depressive Disorder, Major|Suicidality |
2023-06-17 |
69% |
2023-09-29 |
|
| ACTRN12619000108112 | P3 |
Not yet recruiting |
Mucositis|Digestive System Cancer|Skin Cancer|Liver Cancer|Mouth Cancer|Colorectal Cancer|Gastrointestinal Cancer|Oropharyngeal Cancer|Intestinal Diseases |
2022-02-11 |
2024-11-19 |
Treatments |
|
| Ketamine Trial for Acute suicidality (KETA) | P2 |
Active, not recruiting |
Suicidality |
2024-06-08 |
2022-03-13 |
Treatments |
|
| 2021-003258-21 | P2 |
Active, not recruiting |
Healthy Volunteers |
2023-05-19 |
2022-03-13 |
Treatments |
|
| 2021-004927-34 | P2 |
Completed |
Depressive Disorder, Treatment-Resistant |
2023-05-10 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| IRB00331675 | P2 |
Not yet recruiting |
Depressive Disorder, Major|Suicidality |
2023-03-15 |
66% |
2022-06-15 |
Primary Endpoints|Treatments |
| KARMA-Dep (2) | P3 |
Active, not recruiting |
Depressive Disorder, Major |
2022-12-20 |
2022-03-13 |
Treatments |
|
| CTR20240561 | P1 |
Recruiting |
Depressive Disorder, Treatment-Resistant |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| PSYCH007 | P2 |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
None |
2024-08-29 |
Treatments |
|
| ACTRN12618001135202 | P1 |
Not yet recruiting |
Depressive Disorder |
None |
2024-08-29 |
Treatments|Trial Status |
|
| ACTRN12616001351404 | P1 |
Not yet recruiting |
Depressive Disorder |
None |
2024-08-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |